US Patent 4,880,823 (Nicardipine HCl): What Is Actually Claimed, and Where the Landscape Tightens
United States Patent 4,880,823 claims a specific stability-controlled nicardipine hydrochloride (nicardipine HCl) injectable formulation and two corresponding manufacturing processes. The scope is anchored to four measurable constraints:
1) Drug concentration in the ampoule: 0.04 to 0.6 w/v% nicardipine HCl
2) Polyhydric alcohol excipient load: 2 to 7 w/v%
3) Acidic pH window: pH 2.5 to 5
4) Stability performance: after 12 weeks at 60°C, nicardipine HCl remaining is 69.24% to 74.39%
Dependent claims narrow excipient identity (selected polyhydric alcohols) and narrow additional concentration bands for nicardipine HCl. Process claims mirror the formulation limits via dissolution and pH adjustment.
What Is the Patent’s Claim Scope? (Independent vs Dependent)
Claim 1: Formulation defined by composition plus a stability endpoint
Independent claim 1 defines the product by four elements that are not independent in practice:
- Dosage form / presentation: “stable, injectable composition … in ampoule form”
- Aqueous nicardipine HCl solution containing:
- 0.04 to 0.6 w/v% nicardipine HCl
- 2 to 7 w/v% of a polyhydric alcohol
- pH 2.5 to 5
- Stability limitation:
- After 12 week storage at 60°C, nicardipine HCl remaining is 69.24% to 74.39%
Scope impact: The stability endpoint is a performance limit that can narrow coverage even if a competing formulation lands inside the compositional ranges. In infringement analysis, a court often treats such endpoint limitations as product-defining features. A competitor with “same ranges” but materially different stability could fall outside claim 1.
Claim 2: Excipient identity is a closed list
Claim 2 restricts the polyhydric alcohol to one of:
- sorbitol
- mannitol
- xylitol
- propylene glycol
- glycerol
- inositol
Scope impact: Generic “polyols” outside this list are not within claim 2, and since claim 2 is dependent, the excipient identity becomes an additional requirement if asserting claim 2.
Claim 3: Process claim tied to formulation limits
Claim 3 claims a process corresponding to “producing a stable … composition of claim 8” (the text you provided references claim 8, but the earlier independent is claim 1). The core process limitations are:
- Dissolve nicardipine HCl and a polyhydric alcohol in water
- Use polyhydric alcohol at 2 to 7 w/v% of the whole injection
- Adjust pH to 2.5 to 5
Scope impact: The process claim is composition-anchored but does not explicitly include the 12-week/60°C stability endpoint in the text you supplied. In practice, process claims can be harder to enforce if competitors make equivalent end products using a different route, but here the process is still constrained by the same key ranges.
Claim 4: Closed list for process excipient identity
Claim 4 repeats the excipient list from claim 2.
Claim 5: Narrower nicardipine concentration band
Claim 5 depends on claim 1 and narrows nicardipine HCl concentration to:
Scope impact: Claim 5 narrows only the nicardipine band; it still inherits excipient load, pH, and the stability endpoint from claim 1.
Claim 6: Process corresponding to claim 5
Claim 6 is a process linked to the narrower nicardipine range of claim 5, with:
- Polyhydric alcohol 2 to 7 w/v%
- Adjust pH to 2.5 to 5
- Dissolve nicardipine HCl and polyhydric alcohol in water
Claim 7: Closed excipient list for claim 6
Claim 7 repeats the excipient list.
What Does This Mean for Freedom-to-Operate? (Infringement vectors and carve-outs)
1) The stable endpoint is a major narrowing feature
If a competitor formulation fits:
- nicardipine HCl 0.04 to 0.6 w/v%
- polyhydric alcohol 2 to 7 w/v%
- pH 2.5 to 5
…they still need to match the specific stability window:
- 69.24% to 74.39% nicardipine remaining after 12 weeks at 60°C
A competitor that improves stability beyond 74.39% (or drops below 69.24%) can fall outside claim 1 even if the composition looks similar.
Practical implication: Stability testing protocol consistency matters (assay method, sampling, storage conditions). Because the claim uses an endpoint with a numerical range, enforcement often turns on whether a challenger can reproduce that endpoint under the claim’s conditions.
2) Excipient selection is a hard boundary
Claim 2 and claim 4/7 restrict “polyhydric alcohol” to a defined set. If a competitor uses a different polyol or polyhydric alcohol not listed (even if it functionally stabilizes), it can avoid dependent-claim scope. Claim 1 itself refers generally to “a polyhydric alcohol,” but dependent claims narrow; the independent claim may still capture other polyols if the court interprets “polyhydric alcohol” broadly enough. A claims strategy in litigation often attacks interpretation of “polyhydric alcohol” against the specification and prosecution history.
3) pH is a narrow working window
pH 2.5 to 5 is broad relative to ultra-acidic formulations, but still excludes:
- neutral formulations
- more acidic formulations outside 2.5
- higher pH buffers commonly used for injectables
4) The ampoule requirement is a form factor
Claim 1 includes “ampoule form.” If a competitor markets the same solution in a vial, syringe, or container system, the literal claim might be argued not to read onto that form unless “ampoule form” is construed broadly.
Scope Map: Claim Elements as a “Design Space”
Claim 1 design-space constraints
| Element |
Range / Requirement |
Claim location |
| Container |
Ampoule form |
Claim 1 |
| Nicardipine HCl concentration (w/v%) |
0.04 to 0.6 |
Claim 1 |
| Polyhydric alcohol (w/v%) |
2 to 7 |
Claim 1 |
| pH |
2.5 to 5 |
Claim 1 |
| Stability endpoint |
12 weeks @ 60°C: 69.24% to 74.39% nicardipine HCl remaining |
Claim 1 |
Dependent narrowing
| Claim |
Added constraint |
How it narrows |
| Claim 2 |
Polyhydric alcohol is one of: sorbitol, mannitol, xylitol, propylene glycol, glycerol, inositol |
Limits excipient identity |
| Claim 5 |
Nicardipine HCl is 0.1 to 0.6 w/v% |
Removes low-end segment (0.04 to 0.099999%) |
| Claims 4 and 7 |
Same excipient list applied to process |
Limits process excipient identity |
| Claims 3 and 6 |
Process defined by dissolution and pH adjustment within same ranges |
Limits manufacturing route and formulation targets |
How Does This Shape the Prior-Art and “Patent Landscape” Question?
With only the claim set provided, the landscape can be characterized at the claim-architecture level, not by identifying each cited document. The reason: the patent landscape is driven by (1) what other patents and publications disclosed nicardipine HCl injectables, (2) which used polyols and acid pH, and (3) whether they included stability endpoints in the claims. Without the patent text’s background, specification, and cited references, a complete citation-based landscape cannot be produced here.
That said, the claim architecture signals where novelty and differentiation likely resided:
- Stability performance is claimed numerically (not merely “stable”).
- Polyhydric alcohol and pH are bound to specific ranges, implying prior disclosures existed with partial overlap.
- Dependent claims lock excipient identity to common polyols, suggesting the inventive selection was tied to stability within those ranges.
Key Landscape Takeaways for Competitors and Investors
1) The numeric stability endpoint is the strongest “barrier to entry”
Most generic or reformulation efforts focus on:
- matching API concentration
- matching buffer/pH
- adding conventional stabilizers
This patent claims a narrow stability band at a defined stress condition. That turns the formulation into a target that must pass a specific stability metric, not just a general “stable” standard.
2) Avoidance paths exist in three claim dimensions
- Stability outside 69.24% to 74.39% remaining at 12 weeks/60°C
- Excipient outside the closed list (for dependent-claim avoidance)
- Container form argument if not an ampoule
Combinations can strengthen noninfringement positions.
3) Process claims are range-based but do not appear to include the stability endpoint
If the process claims are construed without an explicit stability requirement, then the manufacturing “route” may be easier to replicate with slight changes that avoid the product claim. Practically, though, competent litigators will attempt to connect the endpoint limitation back to the “stable composition” product for claim construction.
Key Takeaways
- US 4,880,823 claims a nicardipine HCl injectable ampoule defined by API concentration (0.04 to 0.6 w/v%), polyhydric alcohol (2 to 7 w/v%), and pH (2.5 to 5) plus a numerical stability endpoint: 69.24% to 74.39% remaining after 12 weeks at 60°C.
- Dependent claims add a closed excipient list (sorbitol, mannitol, xylitol, propylene glycol, glycerol, inositol) and narrow nicardipine to 0.1 to 0.6 w/v%.
- Process claims recite dissolution of nicardipine HCl and polyhydric alcohol and pH adjustment within the same key ranges, with excipient identity constraints in dependent process claims.
- The strongest enforceable narrowing feature is the stability window, which can exclude formulations that otherwise match the compositional ranges.
FAQs
1) Does matching the concentration and pH automatically infringe claim 1?
No. Claim 1 also requires the 12-week at 60°C stability metric to be within 69.24% to 74.39% nicardipine HCl remaining.
2) Can using a different polyol avoid the dependent claims?
Yes. Claims 2/4/7 limit polyhydric alcohol identity to a specific list. A polyhydric alcohol outside that list avoids those dependent claims.
3) What part of the claims is most likely to be contested in litigation?
The numerical stability endpoint and how it is measured under the same conditions (assay, sampling, storage protocol).
4) Do the process claims require proving stability after storage?
The process claims you provided define steps (dissolution and pH adjustment within ranges). The excerpt does not explicitly add the stability endpoint into the process steps, making claim construction and nexus to “stable composition” central.
5) What is the practical “design target” for a downstream formulation?
Land inside or outside:
- nicardipine HCl concentration band
- polyhydric alcohol band
- pH band
- and, critically, the stability endpoint band.
References
[1] United States Patent 4,880,823.
